Pharmalucence partners with Integrated Project Services (IPS) for Design and Construction of State-of-the-Art Pharmaceutical Production Facility in Billerca MA.
Pharmalucence receives FDA approval expanding the route of administration and use of its Sulfur Colloid Injection (SCI) to include location of lymph nodes in breast cancer patients.
Pharmalucence Announces Purchase of New Property in Billerica MA. To be Developed into New Corporate Headquarters and State-of-the-Art Drug Manufacturing Facility, beginning Summer 2010.
To be Developed into New Corporate Headquarters and State-of-the-Art Drug Manufacturing Facility, beginning Summer 2010.
Pharmalucence Announces Approval of Generic version of Cardiolite™ Kit for the Preparation of Technetium Tc-99m Sestamibi Injection.
Pharmalucence Announces Approval of Generic version of Choletec™ Kit for the Preparation of Technetium Tc-99m Mebrofenin.